Skip to main content
Tianhong Li, MD, Oncology, Sacramento, CA

Tianhong Li MD


Assistant Professor, Internal Medicine, UC, Davis School of Medicine

Join to View Full Profile
  • 2278 45th StreetSacramento, CA 95817

  • Phone+1 916-734-5959

  • Fax+1 916-703-5265

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2000 - 2003
  • Icahn School of Medicine at Mount Sinai/Beth Israel
    Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1997 - 2000
  • Beijing Medical University
    Beijing Medical UniversityClass of 1989

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2009 - 2025
  • NY State Medical License
    NY State Medical License 2000 - 2010
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • OncoImmune Launches First-in-Human Clinical Trial for ONC-392 – the Anti-CTLA-4 Antibody That Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy
    OncoImmune Launches First-in-Human Clinical Trial for ONC-392 – the Anti-CTLA-4 Antibody That Preserves CTLA4 Recycling for Safer and More Effective ImmunotherapySeptember 23rd, 2020
  • Liquid, the Latest Advance in the Company’s Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer
    Liquid, the Latest Advance in the Company’s Liquid Biopsy Test for Solid Tumors in Patients with Advanced CancerSeptember 24th, 2018

Grant Support

  • Targeting Integrins in Lung CancerVA NORTHERN CALIFORNIA HEALTH CARE SYS2021–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: